Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T23:24:19.850Z Has data issue: false hasContentIssue false

Chap. 38 - DYSPORT

from PART THREE - FILLERS AND NEUROTOXINS

Published online by Cambridge University Press:  06 July 2010

By
Bernard Rossi
Edited by
Sorin Eremia
Sorin Eremia
Affiliation:
University of California, Los Angeles, School of Medicine
Get access

Summary

Following the publication by J. D. A. Carruthers in 1992, botulinum toxin injections started being used for the treatment of wrinkles caused by certain muscle hyperactivity.

The botulinum toxins type A (BtxA), developed by Allergan Inc. in the United States (BOTOX) and by Beaufour Ipsen in Europe (Dysport), have a parallel history, both being initially used for the treatment of muscle spasms. BOTOX was first, being introduced in the United States in 1985, while Dysport started being used in Europe in 1988. (Dysport is also distributed in France by Gallderma under the name AZZALURE.)

They are both very effective and reliable products. Long-term use in large numbers of patients has demonstrated a lack of secondary effects other than those predictable due to diffusion of the toxin to muscles adjacent to those for which treatment was intended. The site of action of botulinum toxins is shown in Figure 38.1. Over time, improved understanding of anatomy, use of appropriate injection volumes, and improved injection techniques have greatly reduced the incidence of these types of complications.

  • This empirical knowledge was recently confirmed by results of the scientific studies conducted by Dr. B. Ascher to obtain certification for the product in France. There were nine international well designed clinical studies involving 3,500 patients and up to 6 months of follow-up. Several of these studies have been published: Two Phase II dose-finding studies (Ascher 2004, Monheit 2007)

  • One Phase II safety dose1, and one Phase III single-treatment studies (Rzany 2006)

  • One Phase III repeat-treatment studies (Ascher 2005)

  • […]

Type
Chapter
Information
Office-Based Cosmetic Procedures and Techniques , pp. 166 - 170
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Denervation techniques for facial rejuvenation. Dermatol. Surg. 1998;24(11). Special issue.
Cosmetic use of botulinum toxin. Plast. Reconstr. Surg. 2003; 112(5). Special issue.
Ascher, B, Rossi, B. PMID: 15518953. Botulinum toxin and wrinkles: few side effects and effective combining procedures with other treatments. Ann. Chir. Plast. Esthet. 2004;49:537–52.CrossRefGoogle ScholarPubMed
Ascher, B, et al. A multicentre, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J. Am. Acad. Dermatol. 2004;51:223–33.CrossRefGoogle Scholar
Ascher, B, Zakine, B, Kestemont, P, et al. Botulinum Toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surg. 2005;25:365–75.CrossRefGoogle ScholarPubMed
Ascher, B, Rzany, B, and the Smile Group. Reproducibility of two four-point clinical severity scores for lateral canthal lines (crow's feet). Presented at European Academy of Dermatology and Venerology Oct. 2006, Rhodes, Greece, and Dermatol Surg. In Press 2009.
Kranz, G, Haubenberger, D, Voller, B, et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov. Disord. 2009;24(2):231–6.CrossRefGoogle Scholar
Lowe, NJ, Ascher, B, Heckmann, M, et al. Btox Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety of Botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257–62.CrossRefGoogle Scholar
Monheit, G, Carruthers, A, Brandt, F, et al. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1):S51–9.CrossRefGoogle ScholarPubMed
Moy, R, Maas, C, Monheit, G, et al. Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):77–83.CrossRefGoogle ScholarPubMed
Pickett, A, Caird, D. Comparison of type A botulinum toxin products in clinical use. J Clin Pharm Therapeut. 2008;33:327–328.CrossRefGoogle ScholarPubMed
Pickett, A. Dysport((R)): Pharmacological properties and factors that influence toxin action. Toxicon. 2009.CrossRefGoogle ScholarPubMed
Pickett, A, Dodd, S, Rzany, B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Osmet Laser Ther 2008;10(3):181–3.CrossRefGoogle ScholarPubMed
Ranoux, D, Gury, C, Fondarai, J, et al. Retrospective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J. Neurol. Neurosurg. Psychiatry 2002;72:459–62.Google Scholar
Rzany, B, Ascher, B, Fratila, A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142(3):320–6.CrossRefGoogle ScholarPubMed
Rzany, B, Dill-Mueller, D, Grablowitz, D, et al. Repeated botulinum toxin A injections for the treatment lines in the upper face: a retrospective study of 103 treatments in 945 patients. Dermatol Surg. 2007;33(1):S18–25.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • DYSPORT
  • Edited by Sorin Eremia, University of California, Los Angeles, School of Medicine
  • Book: Office-Based Cosmetic Procedures and Techniques
  • Online publication: 06 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511674839.039
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • DYSPORT
  • Edited by Sorin Eremia, University of California, Los Angeles, School of Medicine
  • Book: Office-Based Cosmetic Procedures and Techniques
  • Online publication: 06 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511674839.039
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • DYSPORT
  • Edited by Sorin Eremia, University of California, Los Angeles, School of Medicine
  • Book: Office-Based Cosmetic Procedures and Techniques
  • Online publication: 06 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511674839.039
Available formats
×